Endothelial cell (EC) activation and dysfunction have been linked to a variety of vascular inflammatory disease states including atherosclerosis-the major cause of morbidity and mortality in Western Societies. Accumulating studies highlight a critical role for enhanced NF-kB pathway activation in atherosclerotic tissues including the vascular endothelium. Proinflammatory cytokines and proatherogenic risk factors such as hyperlipidemia lead to NF-kB activation, an effect that confers pro-adhesive, pro-thrombotic properties to ECs. Therefore, suppressing the inflammatory response in the vascular endothelium may provide a novel therapeutic approach to limit atherothrombosis. MicroRNAs (miRNAs) are small, single-stranded, non-coding RNAs capable of repressing gene expression by base pairing to the 3'untranslated regions (3'-UTRs) of mRNA targets and are involved in a variety of pathophysiological processes including the regulation of immune and inflammatory responses. However, the role of microRNAs in atherosclerotic-associated endothelial activation remains poorly defined. We undertook a microarray profiling approach in endothelial cells (ECs) and identified that miR-181b expression is rapidly reduced in response to TNF-a and in the vascular endothelium from atherosclerotic-prone mice - observations that are recapitulated in human inflammatory paradigms in vivo. Based on our preliminary studies, we find that miR-181b overexpression inhibited TNF-a-induced NF-kB-responsive targets including adhesion molecules (e.g. VCAM-1, E-selectin), chemokines (e.g. CX3CL1, CXCL1), and proinflammatory mediators (e.g. COX-2, PAI-1) that are critical to lesion formation, composition, or pre-disposition to thrombosis. Gain and loss-of function studies reveal that miR-181b potently inhibited leukocyte adhesion to endothelial monolayers, whereas inhibition of miR-181b had the opposite effect. Mechanistically, we find that MiR-181b suppressed the activation of the NF-?B pathway by binding uniquely to the 3'UTR of importin-a3, a protein involved in the nuclear translocation of NF-?B, and reduced its expression. Finally, systemic intravenous administration of miR-181b mimics reduced EC activation and leukocyte accumulation in vivo. These observations provide the foundation for the central hypothesis that miR-181b may serve as a critical regulator of EC activation and vascular homeostasis. To better understand the precise role of miR-181b in NF-kB signaling and EC activation, three aims are proposed.
In Aim1, we will delineate the upstream mechanisms governing miR-181b expression in ECs.
In Aim 2, we will determine the molecular basis for miR-181b's ability to regulate NF-kB signaling and EC activation.
In Aim 3, we will explore the effect of altered miR-181b expression on acute and chronic vascular inflammation. The results of these studies will provide insights regarding miR-181b function in EC biology, vascular inflammation, and atherothrombosis and may provide new targets for anti-inflammatory therapy.
The activation of the vascular endothelium is a characteristic feature seen in atherosclerosis and other chronic inflammatory diseases, an effect that may promote disease progression leading to heart attack, stroke, or peripheral vascular disease. We have identified a novel microRNA, termed miR- 181b, that is rapidly reduced in response to pro-inflammatory cytokines in endothelial cells and our studies indicate that miR-181b may act to dampen vascular inflammation within the vessel wall. The proposed studies will provide a detailed understanding underlying the function of this factor with the goal of developing novel therapies for the treatment of acute and chronic inflammatory disease.
|Feinberg, Mark W (2016) No small task: therapeutic targeting of Lp(a) for cardiovascular disease. Lancet 388:2211-2212|
|Lin, Jibin; He, Shaolin; Sun, Xinghui et al. (2016) MicroRNA-181b inhibits thrombin-mediated endothelial activation and arterial thrombosis by targeting caspase recruitment domain family member 10. FASEB J 30:3216-26|
|Feinberg, Mark W (2016) MicroRNAs as pathophysiological targets: An emerging nexus for personalized medicine in heart failure? Trends Cardiovasc Med 26:111-4|
|Feinberg, Mark W; Moore, Kathryn J (2016) MicroRNA Regulation of Atherosclerosis. Circ Res 118:703-20|
|Icli, Basak; Nabzdyk, Christoph S; Lujan-Hernandez, Jorge et al. (2016) Regulation of impaired angiogenesis in diabetic dermal wound healing by microRNA-26a. J Mol Cell Cardiol 91:151-9|
|Icli, Basak; Feinberg, Mark W (2016) Plasticity of Arterial and Venous Endothelial Cell Identity: Some Nerve! Circ Res 119:574-6|
|Sun, Xinghui; Lin, Jibin; Zhang, Yu et al. (2016) MicroRNA-181b Improves Glucose Homeostasis and Insulin Sensitivity by Regulating Endothelial Function in White Adipose Tissue. Circ Res 118:810-21|
|Feinberg, Mark W (2015) Fine-tuning innate and adaptive immune responses: another KLFhanger. Focus on ""KrÃ¼ppel-like factor KLF10 regulates transforming growth factor receptor II expression and TGF-Î² signaling in CD8+ T lymphocytes"". Am J Physiol Cell Physiol 308:C359-61|
|Khedkar, Santosh A; Sun, Xinghui; Rigby, Alan C et al. (2015) Discovery of small molecule inhibitors to KrÃ¼ppel-like factor 10 (KLF10): implications for modulation of T regulatory cell differentiation. J Med Chem 58:1466-78|
|Andreou, Ioannis; Sun, Xinghui; Stone, Peter H et al. (2015) miRNAs in atherosclerotic plaque initiation, progression, and rupture. Trends Mol Med 21:307-18|
Showing the most recent 10 out of 23 publications